Gilead CEO O'Day sells 115,640 shares at $150

Gilead Sciences chairman and CEO Daniel P. O'Day reported an automatic insider transaction involving stock options and common shares.

Rhea-AI Filing Summary

Gilead Sciences chairman and CEO Daniel P. O'Day reported an automatic insider transaction involving stock options and common shares. On February 5, 2026, he exercised 115,640 non-qualified stock options at a price of $66.01 per share and received the same number of common shares.

That same day, he sold 115,640 shares of Gilead common stock at $150 per share under a Rule 10b5-1 trading plan adopted on February 28, 2025. After these transactions, he directly owned 613,912 shares of Gilead common stock.

Insider Trade Summary

Exercise and Sale: 115,640 shares ($9.71M approx. pre-tax spread)

Exercise and Sale 3 txns

Insider O'Day Daniel Patrick

Role Chairman & CEO

Sold 115,640 shs ($17.35M)

Approx. gross sale proceeds $17.35M

Approx. exercise cost $7.63M

Approx. pre-tax spread $9.71M

Type	Security	Shares	Price	Value
Exercise	Non-qualified Stock Option (Right to Buy)	115,640	$0.00	$0.00
Exercise	Common Stock	115,640	$66.01	$7.63M
Sale	Common Stock	115,640	$150.00	$17.35M

Holdings After Transaction: Non-qualified Stock Option (Right to Buy) — 0 contracts (Direct); Common Stock — 613,912 shares (Direct)

Footnotes (2)

1. F1. The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 28, 2025.
2. F2. The stock options have a four-year vesting schedule. 25% of the stock options vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Gilead (GILD) CEO Daniel O'Day report?

Daniel O'Day reported exercising 115,640 non-qualified stock options and selling 115,640 Gilead common shares. The options were exercised at $66.01 per share, and the shares were sold at $150 per share in a planned Rule 10b5-1 transaction.

How many Gilead (GILD) shares does CEO Daniel O'Day own after this Form 4?

After the reported transactions, Daniel O'Day directly owns 613,912 Gilead common shares. This reflects the exercise of 115,640 stock options and the same-day sale of 115,640 shares at $150 per share disclosed in the Form 4.

Was the Gilead (GILD) CEO’s share sale under a Rule 10b5-1 plan?

Yes. The filing states the transaction was made under a Rule 10b5-1 trading plan adopted on February 28, 2025. Such plans pre-schedule trades, allowing executives to sell shares systematically over time under prearranged instructions.

What stock options did Gilead (GILD) CEO Daniel O'Day exercise?

Daniel O'Day exercised 115,640 non-qualified stock options with an exercise price of $66.01 per share. These options were scheduled to vest over four years, with 25% after one year and the remaining 75% vesting 6.25% quarterly until fully vested.

What prices were involved in the Gilead (GILD) CEO’s Form 4 trades?

The Form 4 reports an exercise price of $66.01 per share for 115,640 non-qualified stock options. The corresponding 115,640 Gilead common shares were then sold at a reported sale price of $150 per share on February 5, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/06/2026 - 04:22 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

O'Day Daniel Patrick

(Last) (First) (Middle)

333 LAKESIDE DRIVE

(Street)

FOSTER CITY CA 94404

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
GILEAD SCIENCES, INC. [ GILD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chairman & CEO

3. Date of Earliest Transaction (Month/Day/Year)
02/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/05/2026		M(1)		115,640	A	$66.01	729,552	D
Common Stock	02/05/2026		S(1)		115,640	D	$150	613,912	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-qualified Stock Option (Right to Buy)	$66.01	02/05/2026		M(1)			115,640	(2)	03/01/2029	Common Stock	115,640	$0	0	D

Explanation of Responses:

1. The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 28, 2025.

2. The stock options have a four-year vesting schedule. 25% of the stock options vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

Remarks:

	/s/ Edward S. Son by Power of Attorney for Daniel P. O'Day	02/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.